Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2006, Article ID 38458, 6 pages
http://dx.doi.org/10.1155/MI/2006/38458
Research Communication

Serum Levels of Tissue Inhibitors of Metalloproteinase 2 in Patients With Systemic Sclerosis With Duration More Than 2 Years: Correlation With Cardiac and Pulmonary Abnormalities

1Rheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Cairo, Egypt
2Dermatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
3Medical Biochemistry Department, Faculty of Medicine, Cairo University, Cairo, Egypt
4Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt
5Medical Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Received 21 July 2006; Revised 15 October 2006; Accepted 15 October 2006

Copyright © 2006 Amira Shahin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C Mauch, B Eckes, N Hunzelmann, T Oono, E Kozlowska, and T Krieg, “Control of fibrosis in systemic scleroderma,” Journal of Investigative Dermatology, vol. 100, no. 1, pp. 92S–96S, 1993. View at Publisher · View at Google Scholar
  2. J Varga and S A Jimcncz, “Pathogenesis of scleroderma, cellular aspects,” in Systemic Sclerosis, P J Clements and D E Furst, Eds., pp. 304–321, Williams and Wilkins, Baltimore, Md, 1996. View at Google Scholar
  3. L Mattila, K Airola, M Ahonen et al., “Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts,” Journal of Investigative Dermatology, vol. 110, no. 4, pp. 416–421, 1998. View at Publisher · View at Google Scholar · View at PubMed
  4. T Baker, S Tickle, H Wasan, A Docherty, D Isenberg, and J Waxman, “Serum metalloproteinases and their inhibitors: markers for malignant potential,” British Journal of Cancer, vol. 70, no. 3, pp. 506–512, 1994. View at Google Scholar
  5. J Uitto, E A Bauer, and A Z Eisen, “Scleroderma. Increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture,” Journal of Clinical Investigation, vol. 64, no. 4, pp. 921–930, 1979. View at Google Scholar
  6. E C LeRoy, “Increased collagen synthesis by scleroderma skin fibroblasts in vitro. A possible defect in the regulation or activation of the scleroderma fibroblast,” Journal of Clinical Investigation, vol. 54, no. 4, pp. 880–889, 1974. View at Google Scholar
  7. S A Young-Min, C Beeton, R Laughton et al., “Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls,” Annals of the Rheumatic Diseases, vol. 60, no. 9, pp. 846–851, 2001. View at Publisher · View at Google Scholar
  8. K Kikuchi, M Kubo, S Sato, M Fujimoto, and K Tamaki, “Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis,” Journal of the American Academy of Dermatology, vol. 33, no. 6, pp. 973–978, 1995. View at Publisher · View at Google Scholar
  9. N Yazawa, K Kikuchi, H Ihn et al., “Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis,” Journal of the American Academy of Dermatology, vol. 42, no. 1 pt 1, pp. 70–75, 2000. View at Publisher · View at Google Scholar
  10. B Dziankowska-Bartkowiak, E Waszczykowska, M Luczyńska, A Zalewska, and A Sysa-Jędrzejowska, “Serum levels of tissue inhibitor of metalloproteinases 2 in systemic sclerosis: a preliminary study,” Medical Science Monitor, vol. 8, no. 2, pp. CR108–CR112, 2002. View at Google Scholar
  11. K T Weber, R Pick, J S Janicki, G Gadodia, and J B Lakier, “Inadequate collagen tethers in dilated cardiopathy,” American Heart Journal, vol. 116, no. 6 pt 1, pp. 1641–1646, 1988. View at Publisher · View at Google Scholar
  12. Z Gunja-Smith, A R Morales, R Romanelli, and J F Jr Woessner, “Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: role of metalloproteinases and pyridinoline cross-links,” American Journal of Pathology, vol. 148, no. 5, pp. 1639–1648, 1996. View at Google Scholar
  13. Z Werb and C M Alexander, “Proteinases and matrix degradation,” in Textbook of Rheumatology, W N Kelly, E D Harris, S Ruddy, and C B Sledge, Eds., pp. 248–268, WB Saunders, New York, NY, 1993. View at Google Scholar
  14. W G Stetler-Stevenson, “Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix,” American Journal of Pathology, vol. 148, no. 5, pp. 1345–1350, 1996. View at Google Scholar
  15. J F Jr Woessner, “Matrix metalloproteinases and their inhibitors in connective tissue remodeling,” FASEB Journal, vol. 5, no. 8, pp. 2145–2154, 1991. View at Google Scholar
  16. S C Tyagi, S Kumar, D J Voelker, H K Reddy, J S Janicki, and J J Curtis, “Differential gene expression of extracellular matrix components in dilated cardiomyopathy,” Journal of Cellular Biochemistry, vol. 63, no. 2, pp. 185–198, 1996. View at Publisher · View at Google Scholar
  17. B Dziankowska-Bartkowiak, E Waszczykowska, A Zalewska, and A Sysa-Jędrzejowska, “Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients,” Mediators of Inflammation, vol. 2005, no. 3, pp. 144–149, 2005. View at Publisher · View at Google Scholar · View at PubMed
  18. A T Masi, G P Rodnan, and T A Medsger, “Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee,” Arthritis and Rheumatism, vol. 23, no. 5, pp. 581–590, 1980. View at Publisher · View at Google Scholar
  19. C E LeRoy, C Black, R Fleischmajer et al., “Scleroderma (systemic sclerosis): classification, subsets and pathogenesis,” Journal of Rheumatology, vol. 15, no. 2, pp. 202–205, 1988. View at Google Scholar
  20. P Clements, P Lachenbruch, J Siebold et al., “Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis,” Journal of Rheumatology, vol. 22, no. 7, pp. 1281–1285, 1995. View at Google Scholar
  21. S Morelli, C Barbieri, A Sgreccia et al., “Relationship between cutaneous and pulmonary involvement in systemic sclerosis,” Journal of Rheumatology, vol. 24, no. 1, pp. 81–85, 1997. View at Google Scholar
  22. K Takeda, A Hatamochi, H Ueki, M Nakata, and Y Oishi, “Decreased collagenase expression in cultured systemic sclerosis fibroblasts,” Journal of Investigative Dermatology, vol. 103, no. 3, pp. 359–363, 1994. View at Publisher · View at Google Scholar
  23. N Yazawa, K Kikuchi, H Ihn et al., “Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis,” Journal of the American Academy of Dermatology, vol. 42, no. 1 pt 1, pp. 70–75, 2000. View at Publisher · View at Google Scholar
  24. L Mattila, K Airola, M Ahonen et al., “Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts,” Journal of Investigative Dermatology, vol. 110, no. 4, pp. 416–421, 1998. View at Publisher · View at Google Scholar · View at PubMed
  25. K Kikuchi, T Kadono, M Furue, and K Tamaki, “Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts,” Journal of Investigative Dermatology, vol. 108, no. 3, pp. 281–284, 1997. View at Publisher · View at Google Scholar
  26. S L Raza and L A Cornelius, “Matrix metalloproteinases: pro- and anti-angiogenic activities,” Journal of Investigative Dermatology Symposium Proceedings, vol. 5, no. 1, pp. 47–54, 2000. View at Publisher · View at Google Scholar · View at PubMed
  27. V-M Kähäri and U Saarialho-Kere, “Matrix metalloproteinases in skin,” Experimental Dermatology, vol. 6, no. 5, pp. 199–213, 1997. View at Google Scholar
  28. J Greene, M Wang, Y E Liu, L A Raymond, C Rosen, and Y E Shi, “Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4,” Journal of Biological Chemistry, vol. 271, no. 48, pp. 30375–30380, 1996. View at Publisher · View at Google Scholar
  29. E Toubi, A Kessel, G Grushko, E Sabo, M Rozenbaum, and I Rosner, “The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity,” Clinical and Experimental Rheumatology, vol. 20, no. 2, pp. 221–224, 2002. View at Google Scholar
  30. C S Zurita-Salinas, E Krötzsch, L Díaz De León, and J Alcocer-Varela, “Collagen turnover is diminished by different clones of skin fibroblasts from early- but not late-stage systemic sclerosis,” Rheumatology International, vol. 24, no. 5, pp. 283–290, 2004. View at Publisher · View at Google Scholar · View at PubMed
  31. P R Brauer and D H Cai, “Expression of tissue inhibitor of metalloproteinases (TIMPs) during early cardiac development,” Mechanisms of Development, vol. 113, no. 2, pp. 175–179, 2002. View at Publisher · View at Google Scholar
  32. D A Siwik and W S Colucci, “Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium,” Heart Failure Reviews, vol. 9, no. 1, pp. 43–51, 2004. View at Publisher · View at Google Scholar · View at PubMed
  33. A A González, A M Segura, K Horiba et al., “Matrix metalloproteinases and their tissue inhibitors in the lesions of cardiac and pulmonary sarcoidosis: an immunohistochemical study,” Human Pathology, vol. 33, no. 12, pp. 1158–1164, 2002. View at Publisher · View at Google Scholar · View at PubMed
  34. S Fujimoto, T Kagoshima, T Nakajima, and K Dohi, “Doppler echocardiographic assessment of left ventricular diastolic function in patients with progressive systemic sclerosis,” Cardiology, vol. 83, no. 4, pp. 217–227, 1993. View at Google Scholar
  35. A P Bogdanov, A G Malov, S V Moiseev, and N G Guseva, “The assessment of left ventricular diastolic function in patients with systemic scleroderma by radionuclide ventriculography,” Terapevticheskii Arkhiv, vol. 67, no. 4, pp. 30–32, 1995. View at Google Scholar
  36. G Valentini, D F Vitale, A Giunta et al., “Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve,” Annals of the Rheumatic Diseases, vol. 55, no. 7, pp. 455–460, 1996. View at Google Scholar
  37. G Valentini and S Maione, “Cardiopathy in systemic sclerosis,” Recenti Progressi in Medicina, vol. 87, no. 11, pp. 557–63, 1996. View at Google Scholar
  38. W A D'Angelo, J F Fries, A T Masi, and L E Shulman, “Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls,” American Journal of Medicine, vol. 46, no. 3, pp. 428–440, 1969. View at Publisher · View at Google Scholar
  39. J B Kostis, J R Seibold, D Turkevich et al., “Prognostic importance of cardiac arrhythmias in systemic sclerosis,” American Journal of Medicine, vol. 84, no. 6, pp. 1007–1015, 1988. View at Publisher · View at Google Scholar
  40. W P Follansbee, “The cardiovascular manifestations of systemic sclerosis (scleroderma),” Current Problems in Cardiology, vol. 11, no. 5, pp. 241–298, 1986. View at Publisher · View at Google Scholar